Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

FDA Approves New Labeling for BMS' Sustiva Describing Long-Term Durability in Treatment-Naive Patients

August 30, 2004

FDA on Thursday approved new labeling for Bristol Myers Squibb's antiretroviral drug Sustiva that describes data from a recent clinical trial showing that the drug is effective at suppressing HIV in people who have taken a Sustiva-containing regimen for three years, the Associated Press reports. In the three-and-a-half year study -- which included 1,266 treatment-naïve, HIV-positive people -- subjects were randomized into three groups: the first group took Sustiva, zidovudine and lamivudine; the second took Sustiva, indinavir and lamivudine; and the third took indinavir, zidovudine and lamivudine. At the end of the study, 48% of patients in the first group had an HIV-1 RNA viral load below 400 copies per milliliter, compared with 40% in the second group and 29% in the third group. The study also found that 43% of patients in the first group had a viral load below 50 copies per milliliter, compared with 31% in the second group and 23% in the third (Associated Press, 8/26). "With this new labeling, health care professionals now have additional information to draw on when creating a durable antiretroviral regimen for their treatment-naïve patients," Anthony Hooper, BMS president of U.S. pharmaceuticals, said (BMS release, 8/26).

Back to other news for August 30, 2004


Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2004 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
More HIV News
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

Tools
 

Advertisement